QR-Code

Development of a novel Bruton’s tyrosine kinase inhibitor that exerts anti-cancer activities potentiates response of chemotherapeutic agents in multiple myeloma stem cell-like cells

Despite recent improvements in multiple myeloma (MM) treatment, MM remains an incurable disease and most patients experience a relapse. The major reason for myeloma recurrence is the persistent stem cell-like population. It has been demonstrated that overexpression of Bruton’s tyrosine kinase (BTK)...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Weam Othman Elbezanti, Omar S. Al-Odat, Robert Chitren, Jaikee Kumar Singh, Sandeep Kumar Srivastava, Krishne Gowda, Shantu Amin, Gavin P. Robertson, Venkatesh V. Nemmara, Subash C. Jonnalagadda, Tulin Budak-Alpdogan, Manoj K. Pandey
Format: Artigo
Sprache:Inglês
Veröffentlicht: Frontiers Media S.A. 2022-09-01
Schriftenreihe:Frontiers in Pharmacology
Schlagworte:
Bruton’s tyrosine kinase
Btk inhibitor
multiple myeloma
hematological malignancies
multiple myeloma stem cell-like cells
acquired mutation
Online-Zugang:https://www.frontiersin.org/articles/10.3389/fphar.2022.894535/full
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge